Vanguard Capital Management’s bioAffinity Technologies BIAF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.3K Sell
3,701
-2
-0.1% -$17 ﹤0.01% 3966
2026
Q2
$45.1K Hold
3,703
– – ﹤0.01% 3943
2026
Q1
$213K Hold
3,703
– – ﹤0.01% 3790

Other funds holding BIAF

Vanguard Capital Management's BIAF Position: Q3 2026 in Review

Vanguard Capital Management reduced its bioAffinity Technologies (BIAF) stake by 0.05% in Q3 2026, selling an estimated $17 and leaving 3,701 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3966.

Vanguard Capital Management first reported a position in BIAF in Q1 2026 and has held it in 3 quarters since. The position peaked at $213K in Q1 2026. 14 funds tracked by Wall St. Rank hold BIAF as of Q3 2026.

  • Vanguard Capital Management held 3,701 shares of bioAffinity Technologies worth $24.3K as of Q3 2026.
  • Vanguard Capital Management sold 2 bioAffinity Technologies shares in Q3 2026, an estimated $17.
  • bioAffinity Technologies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3966 holding.
  • Vanguard Capital Management first reported a position in bioAffinity Technologies in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's bioAffinity Technologies position peaked at $213K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.